Adam S. Grossman, the President and CEO of ADMA Biologics, Inc., has made notable stock transactions that may impact investor sentiment and the company's market standing. On November 16, 2026, Grossman reported acquiring 15,000 shares of common stock at a price of $5.40 each. Additionally, he disposed of 21,000 shares at a price of $13.72 each. These transactions underscore his active role in managing his ownership stake in the company.
ADMA Biologics, Inc., classified under the SIC code for Biological Products (No Diagnostic Substances), is a key player in the life sciences sector. The company focuses on developing and commercializing specialty biologics for the treatment of infectious diseases and immune deficiencies. Recent filings indicate a series of transactions by Grossman, including multiple filings of Form 4 in November 2026.
The recent filing reveals that Grossman now owns 2,084,777 shares following these transactions. The filing states, "Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025." This plan allows for pre-scheduled trades, which can help avoid allegations of insider trading.
Grossman's actions may affect various stakeholders, including investors, employees, and market analysts, as they gauge the company's future prospects based on his commitment and ownership level. His significant stake in ADMA Biologics positions him as a crucial figure in the company’s strategic direction.
The filing does not specify what happens next regarding Grossman's stock transactions or any potential future filings.
Read Next
Guiheen Lawrence P. Acquires 10,000 Shares of ADMA Biologics
Gilliam Joseph E reports significant stock transactions
Saba Capital Management reveals stock acquisitions in SEC filing
Evans Bronwyn Reports Multiple Stock Transactions
Halozyme CEO Torley Helen Reports Major Stock Transactions
Saba Capital Management purchases 6,800 shares of JOF





